Contrast-enhanced CT chest can confirm the presence of a mediastinal mass, also provides detailed information regarding the mediastinal abnormality, including its location, size, relationship to other structures, and tissue characteristics, particularly involvement/invasion or compression of surrounding structures, which is critical in planning treatment.
- Magnetic resonance (MR) imaging – MR is useful in distinguishing compression versus invasion, particularly in cases of large anterior mediastinal masses.
- Positron emission tomography (PET) – For a mediastinal mass that is suspected to be lymphoma, using 18F-fluorodeoxyglucose (FDG) with fused CT may be performed. This modality can be useful to identify a preferred biopsy site. For tumors found to be PET avid on the initial study, it can be useful in monitoring response to treatment. However, it is important to note that FDG-PET imaging can be misleading because nonmalignant conditions such as teratoma and thymic cysts have been shown to have FDG accumulation in 14 to 42 percent of cases. Besides, normal thymus has been shown to have a maximum standardized uptake value (SUV) of 2.00 to 2.09, and the thymic rebound has also been observed, where patients treated with chemotherapy for another malignancy have been found to have increased PET activity with a mean SUV of 2.89 at a mean interval of 10 months after chemotherapy completion.
- MRI spine – provide a detailed evaluation of posterior mediastinal tumours that are adjacent to the spine.
- Technetium scan – For a suspected ectopic thyroid tissue or a substernal goiter.
- MIBG {meta-iodobenzylguanidine} – for mediastinalpheochromocytoma.
- Scrotal ultrasound – For a mediastinal mass that is suspected or proven to be a germ cell tumour,.
- Ga-68 DOTATATE) PET/CT scan – in staging neuroendocrine tumours of the thymus.